- Home
- GCMG vs PRAX Comparison
GCMG vs PRAX Comparison
Compare GCMG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- PRAX
- Stock Information
- Founded
- GCMG 1971
- PRAX 2015
- Country
- GCMG United States
- PRAX United States
- Employees
- GCMG N/A
- PRAX N/A
- Industry
- GCMG Finance/Investors Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- GCMG Finance
- PRAX Health Care
- Exchange
- GCMG Nasdaq
- PRAX Nasdaq
- Market Cap
- GCMG 631.4M
- PRAX 599.7M
- IPO Year
- GCMG N/A
- PRAX 2020
- Fundamental
- Price
- GCMG $11.51
- PRAX $43.33
- Analyst Decision
- GCMG Hold
- PRAX Strong Buy
- Analyst Count
- GCMG 5
- PRAX 11
- Target Price
- GCMG $13.60
- PRAX $114.73
- AVG Volume (30 Days)
- GCMG 484.4K
- PRAX 287.9K
- Earning Date
- GCMG 08-07-2025
- PRAX 08-12-2025
- Dividend Yield
- GCMG 3.83%
- PRAX N/A
- EPS Growth
- GCMG N/A
- PRAX N/A
- EPS
- GCMG 0.14
- PRAX N/A
- Revenue
- GCMG $530,455,000.00
- PRAX $8,122,000.00
- Revenue This Year
- GCMG $2.72
- PRAX N/A
- Revenue Next Year
- GCMG $12.99
- PRAX $6,358.50
- P/E Ratio
- GCMG $84.60
- PRAX N/A
- Revenue Growth
- GCMG 17.38
- PRAX 270.02
- 52 Week Low
- GCMG $9.56
- PRAX $26.70
- 52 Week High
- GCMG $14.48
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- GCMG 28.67
- PRAX 56.73
- Support Level
- GCMG $11.37
- PRAX $40.86
- Resistance Level
- GCMG $11.95
- PRAX $44.99
- Average True Range (ATR)
- GCMG 0.28
- PRAX 2.50
- MACD
- GCMG -0.08
- PRAX -0.22
- Stochastic Oscillator
- GCMG 10.29
- PRAX 43.40
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.